DiaSys India, a manufacturer of clinical diagnostic equipment and reagents, inaugurated a new production facility at its Navi Mumbai site during the Samvaad 2025 event. The facility expands the company’s production capacity across its clinical chemistry systems, diagnostic reagents, and point-of-care testing (POCT) product lines.
The company manufactures a range of biochemistry analyzers, including the Photometer 505, SYS1000, SYS400pro, SYS200pro, and SYS240pro. It also produces diagnostic reagents under the Ecoline, Respons, and FS series, supporting tests for liver function, cardiac markers, cholesterol, and other metabolic and infectious diseases.
DiaSys India serves as the global center for research, development, and production of POCT devices under the QDx brand. The facility develops portable diagnostic systems such as the QDx InstaLab and specializes in electrochemical biosensors, immunosensors, microfluidics, and lab-on-chip platforms.
One of the devices showcased was the SYS Aurora, which is designed for high-throughput laboratory settings, capable of processing up to 180 tests per hour. The system offers full automation, including hands-off sample loading and result reporting, and includes a wide test menu covering endocrinology, infectious diseases, and tumor markers. Additional features include advanced software for integration with laboratory information systems, a compact design, built-in quality control protocols, and cost-efficiency through reduced reagent waste.
In 2014, DiaSys India acquired the diagnostics division of Piramal India, establishing its local presence with dedicated functions in sales, marketing, R&D, production, and international operations for the QDx brand.
DiaSys Diagnostics India Private Limited operates from its facility in Mahape, Navi Mumbai. The company has been manufacturing in India since 2014 and is a subsidiary of DiaSys Diagnostic Systems GmbH. DiaSys India also exports its products through the company’s global network.